HARMONY BIOSCIENCES HOLDINGS, INC. Pre-Tax Income
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Pre-Tax Income of $93.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was $93.27M, a 87.89% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was $39.69M, a 30.59% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was $40.76M, a 27.42% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was $67.49M, a 8.56% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was $215.06M, a 12.13% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was $191.80M, a 10.62% increase from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was $173.40M, a 65.63% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was $104.69M, a 179.70% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $93.27M 10-Q · filed 2026-08-04 | $132.95M 10-Q · filed 2026-08-04 | $173.71M derived: sum of 3 quarters · filed 2026-08-04 | $241.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $39.69M 10-Q · filed 2026-05-07 | $80.45M derived: sum of 2 quarters · filed 2026-05-07 | $147.94M derived: sum of 3 quarters · filed 2026-05-07 | $197.57M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $40.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $108.25M derived: sum of 2 quarters · filed 2026-02-24 | $157.89M derived: sum of 3 quarters · filed 2026-08-04 | $215.06M 10-K · filed 2026-02-24 |
| 2025-09-30 | $67.49M 10-Q · filed 2025-11-04 | $117.13M derived: sum of 2 quarters · filed 2026-08-04 | $174.30M 10-Q · filed 2025-11-04 | $230.46M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $49.64M 10-Q · filed 2026-08-04 | $106.81M 10-Q · filed 2026-08-04 | $162.97M derived: sum of 3 quarters · filed 2026-08-04 | $225.14M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $57.18M 10-Q · filed 2026-05-07 | $113.33M derived: sum of 2 quarters · filed 2026-05-07 | $175.50M derived: sum of 3 quarters · filed 2026-05-07 | $197.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $56.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $118.33M derived: sum of 2 quarters · filed 2026-02-24 | $140.02M derived: sum of 3 quarters · filed 2026-02-24 | $191.80M 10-K · filed 2026-02-24 |
| 2024-09-30 | $62.17M 10-Q · filed 2025-11-04 | $83.86M derived: sum of 2 quarters · filed 2025-11-04 | $135.65M 10-Q · filed 2025-11-04 | $175.34M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $21.69M 10-Q · filed 2025-08-05 | $73.48M 10-Q · filed 2025-08-05 | $113.17M derived: sum of 3 quarters · filed 2026-02-24 | $165.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $51.78M 10-Q · filed 2025-05-06 | $91.47M derived: sum of 2 quarters · filed 2026-02-24 | $143.31M derived: sum of 3 quarters · filed 2026-02-24 | $187.40M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $39.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $91.52M derived: sum of 2 quarters · filed 2026-02-24 | $135.62M derived: sum of 3 quarters · filed 2026-02-24 | $173.40M 10-K · filed 2026-02-24 |
| 2023-09-30 | $51.83M 10-Q · filed 2024-10-29 | $95.93M derived: sum of 2 quarters · filed 2024-10-29 | $133.71M 10-Q · filed 2024-10-29 | $177.81M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $44.09M 10-Q · filed 2024-08-06 | $81.88M 10-Q · filed 2024-08-06 | $125.98M derived: sum of 3 quarters · filed 2025-02-25 | $133.94M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $37.78M 10-Q · filed 2024-04-30 | $81.88M derived: sum of 2 quarters · filed 2025-02-25 | $89.85M derived: sum of 3 quarters · filed 2025-02-25 | $119.08M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $44.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $52.07M derived: sum of 2 quarters · filed 2025-02-25 | $81.30M derived: sum of 3 quarters · filed 2025-02-25 | $104.69M 10-K · filed 2025-02-25 |
| 2022-09-30 | $7.97M 10-Q · filed 2023-10-31 | $37.20M derived: sum of 2 quarters · filed 2023-10-31 | $60.58M 10-Q · filed 2023-10-31 | $85.06M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $29.23M 10-Q · filed 2023-08-01 | $52.62M 10-Q · filed 2023-08-01 | $77.09M derived: sum of 3 quarters · filed 2024-02-22 | $66.57M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $23.39M 10-Q · filed 2023-05-02 | $47.86M derived: sum of 2 quarters · filed 2024-02-22 | $37.34M derived: sum of 3 quarters · filed 2024-02-22 | $53.43M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $24.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $13.95M derived: sum of 2 quarters · filed 2024-02-22 | $30.04M derived: sum of 3 quarters · filed 2024-02-22 | $37.43M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$10.52M 10-Q · filed 2022-11-01 | $5.57M derived: sum of 2 quarters · filed 2022-11-01 | $12.95M 10-Q · filed 2022-11-01 | $12.74M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $16.09M 10-Q · filed 2022-08-02 | $23.48M 10-Q · filed 2022-08-02 | $23.27M derived: sum of 3 quarters · filed 2023-02-21 | $25.18M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $7.39M 10-Q · filed 2022-05-03 | $7.18M derived: sum of 2 quarters · filed 2023-02-21 | $9.09M derived: sum of 3 quarters · filed 2023-02-21 | $9.06M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | -$208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $1.70M derived: sum of 2 quarters · filed 2023-02-21 | $1.67M derived: sum of 3 quarters · filed 2023-02-21 | -$36.94M 10-K · filed 2023-02-21 |
| 2020-09-30 | $1.91M 10-Q · filed 2021-11-09 | $1.88M derived: sum of 2 quarters · filed 2021-11-09 | -$36.74M 10-Q · filed 2021-11-09 | -$73.18M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$27.00K 10-Q · filed 2021-08-10 | -$38.65M 10-Q · filed 2021-08-10 | -$75.09M derived: sum of 3 quarters · filed 2022-02-28 | -$106.99M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$38.62M 10-Q · filed 2021-05-11 | -$75.06M derived: sum of 2 quarters · filed 2022-02-28 | -$106.96M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$36.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$68.34M derived: sum of 2 quarters · filed 2022-02-28 | -$151.98M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$31.90M 10-Q · filed 2020-11-12 | -$115.54M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |